Clinical Trial Update: 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining Xenon-129 MRI as a biomarker for diagnosis and treatment response in pulmonary arterial hypertension, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Snippet

Sponsor: Bastiaan Driehuys | Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension | Phase 2 | Status: RECRUITING